Compare · AYTU vs HRMY
AYTU vs HRMY
Side-by-side comparison of Aytu BioPharma Inc. (AYTU) and Harmony Biosciences Holdings Inc. (HRMY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYTU and HRMY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- HRMY is the larger of the two at $1.94B, about 97.9x AYTU ($19.8M).
- Over the past year, AYTU is down 10.9% and HRMY is down 2.9% - HRMY leads by 8.0 points.
- AYTU has been more active in the news (11 items in the past 4 weeks vs 5 for HRMY).
- HRMY has more recent analyst coverage (25 ratings vs 3 for AYTU).
- Company
- Aytu BioPharma Inc.
- Harmony Biosciences Holdings Inc.
- Price
- -
- -
- Market cap
- $19.8M
- $1.94B
- 1M return
- -10.95%
- -13.06%
- 1Y return
- -10.95%
- -2.94%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 11
- 5
- Recent ratings
- 3
- 25
Aytu BioPharma Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Latest AYTU
- Aytu BioScience downgraded by Lake Street with a new price target
- SEC Form 10-Q filed by Aytu BioPharma Inc.
- SEC Form 425 filed by Aytu BioPharma Inc.
- Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results
- Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
- Aytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
- Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026
- FDA Approval for ZOLPIMIST issued to AYTU
Latest HRMY
- SEC Form SCHEDULE 13G filed by Harmony Biosciences Holdings Inc.
- SEC Form 10-Q filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
- Amendment: SEC Form 8-K/A filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- Ladenburg Thalmann initiated coverage on Harmony Biosciences with a new price target
- SEC Form 8-K filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
- Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days